Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2024-01-03 Regulatory Filings
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
PureTech to present at the JP Morgan Conference
Regulatory Filings Classification · 100% confidence The document is a short press release, indicated by the RNS Number (4292Y) and the distribution source (RNS, part of the London Stock Exchange). The content announces that the CEO will present at the '42nd Annual J.P. Morgan Healthcare Conference' on a future date. This is an announcement about participation in an external industry event, not a formal regulatory filing like a 10-K, an earnings release (ER), or a proxy statement. Since it is a general, time-sensitive announcement distributed via the RNS system that doesn't fit the specific categories like DIV, ER, or MANG, it falls best under the general regulatory announcement category, RNS, or potentially a Report Publication Announcement (RPA) if it were announcing the publication of a company-specific report. Given it announces participation in a conference, RNS is the most appropriate general regulatory filing category for this type of market communication.
2024-01-03 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title section: 'Transaction in Own Shares'. It details the purchase of ordinary shares as part of a 'Share Buyback Programme' on a specific date (2 January 2024), including volume, high, low, and VWAP prices. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS), which covers share repurchase activities. The presence of the RNS Number and the LSE/FCA context confirms it is a regulatory disclosure, but the specific content points overwhelmingly to POS.
2024-01-03 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an RNS announcement from PureTech Health PLC, dated December 27, 2023. The title explicitly states 'Transaction in Own Shares' and details the purchase of ordinary shares as part of a 'Share Buyback Programme'. The content includes specific transaction dates, volumes, and prices, culminating in an update on the total shares in treasury and in issue. This directly corresponds to the definition of a 'Transaction in Own Shares' filing, which maps to the code POS (Report of the company buying back or selling its own shares (share repurchase/issuance)).
2023-12-27 English
BMY Acquires PRTC Founded Entity Karuna for $14B
M&A Activity Classification · 99% confidence The document is a press release announcing a definitive merger agreement where Bristol Myers Squibb will acquire Karuna Therapeutics for $14.0 billion. It is distributed via RNS (RNS Number : 8322X) and contains details about the transaction, the acquired asset (KarXT), and conference call information. Since this is a major corporate action announcement (acquisition/merger) that is being disseminated through a regulatory news service (RNS), it fits best under the 'M&A Activity' (TAR) category, as it details a takeover proposal. Although it is distributed via RNS, the core subject matter is M&A, making TAR more specific than the general RNS fallback.
2023-12-22 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title section: "Transaction in Own Shares". It details the purchase of ordinary shares as part of a "Share Buyback Programme" and provides granular data on the number of shares purchased, prices paid, and the resulting treasury share balance. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS header confirms it is a regulatory announcement, but the specific content dictates the most precise classification.
2023-12-22 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title section: 'Transaction in Own Shares'. It details the purchase of ordinary shares as part of a 'Share Buyback Programme' on a specific date (20 December 2023), including the number of shares purchased, and the resulting treasury share count and total voting rights. This content directly corresponds to the definition of 'Transaction in Own Shares', which maps to the filing type code POS (Report of the company buying back or selling its own shares (share repurchase/issuance)). The presence of the RNS Number and the LSE/FCA context confirms it is a regulatory disclosure, but the specific subject matter dictates the most precise code.
2023-12-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.